Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re-appointment to the Scientific Advisory Board

1 Dec 2014 07:00

RNS Number : 3368Y
Provexis PLC
01 December 2014
 



1 December 2014

 

Provexis plc

 

Re-appointment of Professor Asim Duttaroy to the Scientific Advisory Board

 

Provexis plc ('Provexis' or the 'Company'), the business that develops and licenses the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce the re-appointment of Professor Asim Duttaroy to the Company's Scientific Advisory Board.

 

Professor Duttaroy was the original inventor of Fruitflow® and he previously served on the Company's Scientific Advisory Board from 2003 to 2011.

 

Professor Duttaroy is a globally recognised expert in the field of nutrition studies; he is currently Group Leader of Chronic Disease at the University of Oslo's Faculty of Medicine, and on 5 November 2014 he was appointed as editor in chief of the international peer reviewed journal Food & Nutrition Research.

 

The Company's Scientific Advisory Board (SAB) is now composed of Professor Asim Duttaroy, the inventor of Fruitflow®, and Dr Niamh O'Kennedy, a research chemist specialising in the field of natural products chemistry. Dr O'Kennedy played a key role in the development of Fruitflow® and the health claim for Fruitflow® which was adopted by the European Food Safety Authority ('EFSA'). The Company's agreements with SAB members include certain confidentiality, non-compete, IP assignment and first right of view provisions.

 

On 18 November 2014 the Company announced it had signed a collaboration agreement with the University of Oslo to undertake further research into the relationship between Fruitflow® and blood pressure regulation, with collaboration work to be led by Professor Duttaroy and Dr O'Kennedy. The company is ideally positioned to develop technologies designed to extend the existing 'healthy blood flow' product claims of Fruitflow®, on a carefully managed and costed basis, with the collaboration expected to be an important step in maximising the opportunities available to commercialise the product.

 

The Company also announced on 18 November 2014 that Professor Duttaroy and Dr O'Kennedy had been granted certain new options over Ordinary Shares under the Provexis 2005 share option scheme, which the Company believes will closely align their interests with those of shareholders.

 

Dawson Buck, Chairman of Provexis, commented:

"We are delighted that Professor Duttaroy has re-joined the Scientific Advisory Board, further strengthening his longstanding relationship with the Company and its key heart-health functional food ingredient, Fruitflow.

 

We believe that Professor Duttaroy will play an important role in maximising the opportunities available to commercialise Fruitflow, to the benefit of shareholder value."

 

 

- ends -

 

For further information please contact:

 

Provexis plc Tel: 07917 670260

Dawson Buck, Chairman enquiries@provexis.com

Ian Ford, Finance Director

 

Cenkos Securities plc Tel: 020 7397 8900

Bobbie Hilliam

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAAFPALPLFFF
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.